Prolonged risk of subtrochanteric and diaphyseal femur fractures after discontinuing alendronate treatment: A nationwide nested case-control study in Taiwan
Conclusion Discontinuation of alendronate therapy did not reduce the risk of subtrochanteric femoral fractures until it was discontinued for >5 years. In conclusion, alendronate use significantly increased the risk of subtrochanteric femoral fractures, and the risk may persist for 5 years after discontinuation.
Source: Journal of Clinical Gerontology and Geriatrics - Category: Geriatrics Source Type: research
More News: Diabetes | Diabetes Mellitus | Endocrinology | Geriatrics | Health Insurance | Insurance | Orthopaedics | Osteoarthritis | Osteoporosis | Stroke | Study